BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 38249077)

  • 1. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
    Shah S
    Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
    Hamad A; Yusubalieva GM; Baklaushev VP; Chumakov PM; Lipatova AV
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraarterial delivery of virotherapy for glioblastoma.
    Srinivasan VM; Lang FF; Kan P
    Neurosurg Focus; 2021 Feb; 50(2):E7. PubMed ID: 33524944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
    Shoaf ML; Desjardins A
    Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
    Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
    Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
    Cuoco JA; Rogers CM; Mittal S
    Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic viruses in lung cancer treatment: a review article.
    Sakhi H; Arabi M; Ghaemi A; Movafagh A; Sheikhpour M
    Immunotherapy; 2024 Feb; 16(2):75-97. PubMed ID: 38112057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses.
    Ali S; Xia Q; Muhammad T; Liu L; Meng X; Bars-Cortina D; Khan AA; Huang Y; Dong L
    Stem Cell Rev Rep; 2022 Feb; 18(2):523-543. PubMed ID: 34319509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.
    Garmaroudi GA; Karimi F; Naeini LG; Kokabian P; Givtaj N
    Oxid Med Cell Longev; 2022; 2022():3142306. PubMed ID: 35910836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Zika Virus: New Option for Glioblastoma Treatment.
    Zhou C; Chen Q; Chen Y; Qin CF
    DNA Cell Biol; 2023 Jun; 42(6):267-273. PubMed ID: 36350682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.
    Ageenko A; Vasileva N; Richter V; Kuligina E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
    Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
    Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers.
    Deng M; Wang Q
    Curr Cancer Drug Targets; 2023; 23(7):505-523. PubMed ID: 36824004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Viruses and Cancer Immunotherapy.
    Malhotra J; Kim ES
    Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.